Thomas D, Boubrit K, Darbois Y, Seebacher J, Seirafi D, Hanania G
Service de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris.
Ann Cardiol Angeiol (Paris). 1994 Jun;43(6):313-21.
In order to be able to offer pregnant artificial heart valve patients a practical management approach enabling reduction of maternal and fetal risks, the authors evaluated 40 pregnancies in 24 women. Thirty one valves had been inserted prior to these pregnancies: 24 mechanical valves and 7 biological valves. Different types of anticoagulation regimens were used in 32 pregnancies, while 8 took place without the use of anticoagulants (biological valves in sinus rhythm). From a clinical standpoint, almost all these pregnancies brought to term took place without cardiac decompensation. They resulted in the birth of 26 live infants, including one premature. One child was born at term with a phocomelia-type malformation and two were stillborn. There were five therapeutic abortions and six spontaneous abortions. There were four cases of thromboses of the artificial valve, three of which occurred in patients on heparin (dose of 5,000 IU/12 h). Three massive thromboses required emergency valve replacement surgery. There were also three embolic accidents, including one which regressed totally in a few hours. Two hemorrhagic complications occurred with subcutaneous heparin during the post-partum period. In practice, we feel that: when a young woman wishing to become pregnant requires valve replacement, a biological device is preferable; oral anticoagulants are contra-indicated during the first three months of pregnancy; the dose of 5,000 IU/12 h of heparin is insufficient to prevent thrombo-embolic accidents; when a mechanical valve is already implanted, the sequential treatment protocol of subcutaneous heparin--oral anticoagulant--subcutaneous heparin, with an initial dose of heparin of 5,000 IU/12 h then adjusted on the basis of APTT, is the best choice.
为了能够为植入人工心脏瓣膜的孕妇提供一种切实可行的管理方法,以降低母婴风险,作者对24名女性的40次妊娠进行了评估。在这些妊娠之前已植入31个瓣膜:24个机械瓣膜和7个生物瓣膜。32次妊娠使用了不同类型的抗凝方案,而8次妊娠未使用抗凝剂(窦性心律的生物瓣膜)。从临床角度来看,几乎所有这些足月妊娠均未发生心脏代偿失调。这些妊娠共分娩26名活婴,其中1名早产。1名足月出生的婴儿患有短肢畸形,2名死产。有5例治疗性流产和6例自然流产。发生了4例人工瓣膜血栓形成,其中3例发生在使用肝素(剂量为5000 IU/12小时)的患者中。3例大面积血栓形成需要紧急进行瓣膜置换手术。还发生了3例栓塞事件,其中1例在数小时内完全消退。产后使用皮下肝素期间发生了2例出血并发症。实际上,我们认为:当希望怀孕的年轻女性需要进行瓣膜置换时,生物装置更为可取;妊娠前三个月禁忌使用口服抗凝剂;5000 IU/12小时的肝素剂量不足以预防血栓栓塞事件;当已经植入机械瓣膜时,皮下肝素 - 口服抗凝剂 - 皮下肝素的序贯治疗方案,初始肝素剂量为5000 IU/12小时,然后根据活化部分凝血活酶时间(APTT)进行调整,是最佳选择。